Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome, also known as ACOS, is a unique disease entity that incorporates the co-existence of both asthma and COPD and is often characterized by a persistent airflow limitation. This indicates that ACOS includes two different clinical phenotypes, which are a result of different underlying mechanisms. The global prevalence of ACOS is estimated to range from 25% to 41%, while it ranges between 12.7–55.2% in COPD and 13.3–61% in asthma. A GINA/GOLD document on ACOS recommended that the diagnosis of ACOS should not be based only on spirometric and syndromic features additionally inflammatory biomarkers such as fractional exhaled nitric oxide (FeNO) and blood eosinophils should be used for differentiating ACOS from COPD and asthma.

Patients with ACOS tend to have worse clinical outcomes such as frequent exacerbations, rapid decline in lung function, and poor health-related quality of life (HRQoL) compared to those with asthma or COPD alone. All these factors contribute to a higher mortality rate in patients with ACOS. A retrospective study conducted by Pleasants et al., reported more dyspnea, higher co-morbidity index, frequent hospitalization, and a higher Bode index (BI) in ACOS patients when compared to asthma and COPD groups. Another study done by Chung et al., reported poor functional exercise capacity in ACOS patients when compared to COPD and asthma groups. Moreover, a recent cross-sectional study also showed lower forced expiratory volume in 1 second (FEV₁) and higher BI in ACOS patients compared to COPD.

Pulmonary rehabilitation (PR) has been well established as a means to alleviate the signs and symptoms of various pulmonary conditions as well as optimize functional capacity, improve exercise tolerance, and HRQoL. The benefit of PR as well

**ABSTRACT**

Objectives: We sought to evaluate the effectiveness of six weeks pulmonary rehabilitation (PR) in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS). Methods: We enrolled 28 patients with ACOS. Fourteen patients were randomly allocated to the PR group, which comprised of supervised endurance training, supervised resistance training, breathing exercises, self management, and education. The other 14 patients were allocated to the control group, who were asked to continue their usual routine strategies for six weeks. All patients were assessed at baseline and after six weeks using the six minute walk test (6MWT), St George Respiratory Questionnaire (SGRQ), pulmonary function test (PFT), and Bode index (BI). Results: We saw a significant improvement in 6MWT (\(p < 0.001\)), SGRQ (\(p = 0.007\)), and BI (\(p < 0.001\)) in the PR group after six weeks compared to the control group. There was no significant difference between the groups for PFT (\(p = 0.182\)) after six weeks. Conclusions: Use of a short-term PR program in ACOS patients results in favorable changes in functional capacity, health-related quality of life, and BI. However, short-term PR was not sufficient to register changes in pulmonary function in these patients.
as its efficacy has been reported previously in both COPD and asthma patients. However, the efficacy of a comprehensive PR program in ACOS patients is largely unknown. Considering the worse clinical course in patients with ACOS, there is a need to assess the effectiveness of PR program in this debilitated population. Therefore, our study aimed to evaluate the effects of a six-week comprehensive PR program on functional capacity, HRQoL, pulmonary function, and BI in patients with ACOS. We hypothesized that a six-week program will result in favorable changes in the outcome variables in patients with ACOS.

**METHODS**

We conducted the study after obtaining ethical clearance from the Institutional Human Ethics Committee of Jamia Millia Islamia, New Delhi, India and from the Metro Ethics Review Board, Metro Hospital Noida, India (16/9/134/JMI/IEC/2017). Patients were diagnosed with ACOS according to syndromic and spirometric features from the GINA/GOLD joint document. The ACOS features which were taken into consideration included: age at onset, pattern and duration of symptoms, pulmonary function, patient's family history, and chest X-ray. Participants in this study fulfilled three or more features of COPD. Furthermore, ACOS patients should have three or more features of asthma as follows: onset before age 20 years, family history of asthma or allergic rhinitis or eczema, normal findings on chest X-ray without severe hyperinflation, common time course in asthmatic patients, variable respiratory symptoms as well as variable expiratory airflow limitation. The common time course included an immediate response to bronchodilator or to inhaled corticosteroids (ICS) over several weeks. Variable respiratory symptoms included shortness of breath that varied over minutes, hours, or days and worsened during the night or early morning. Variable expiratory airflow limitation was defined as improvement in FEV₁ ≥ 200 mL and ≥ 12% from baseline immediately after the use of a bronchodilator or several weeks after the use of ICS. We evaluated these features to confirm ACOS. Furthermore, it was ensured that all patients included in this study were previously investigated for inflammatory markers such as FeNO and eosinophil count. This data was obtained from each patient’s medical record. The exclusion criteria for the subjects included contraindications to PR such as a history of myocardial infarction, angina, and congestive heart failure. Patients with any orthopedic or cognitive impairment that would interfere with the regular participation in the rehabilitation program or with any previous history of thoracic surgical intervention were also excluded. Written informed consent was obtained from all participants, and research procedures were conducted in accordance with the Declaration of Helsinki, 1964.

The number of subjects was determined using G. Power 3.15 software (Franz F, Universität Kiel, Kiel, Germany) based on changes in data of St George Respiratory Questionnaire (SGRQ) in a previous study. Fourteen subjects per group were shown to be necessary including 10% dropouts based on the effect size of 0.30, alpha level of 0.05, and power (1-beta) of 0.80.

Twenty-eight ACOS patients were recruited from the pulmonary outpatient department of the Metro Hospital, Noida, India. Patients were familiarized with the study procedures a week prior to the baseline testing. Baseline testing was performed over two days. On day one, following anthropometric assessment, patients were subjected to a pulmonary function test (PFT) and a six minute walk test (6MWT) with an adequate rest period between the two assessments. On day two, patients were asked to fill the SGRQ and the BI was calculated as described by Celli et al. Following baseline testing, patients were randomly allocated using computer-generated block randomization to either the PR group or the control group. The patients in the PR group participated in a six-week comprehensive PR program in addition to the usual care strategies, whereas the control group received usual care strategies alone. All outcomes measures including PFT, 6MWT, SGRQ, and BI were again evaluated after completion of six weeks study period in both the PR and control group.

All patients performed a PFT (JAEGER, Care Fusion) according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. The ratio of FEV₁/forced vital capacity (FVC), FVC, and FEV₁ were measured. The 6MWT was performed in accordance with the ATS/ERS guidelines and parameters such as dyspnea, oxygen saturation (SpO₂), blood pressure,
and pulse rate were measured at the beginning and end of the test. Each patient was asked to walk at his/her own pace to cover maximum distance possible in the allotted time. The distance covered by the patient in six minutes was recorded and reported in meters and percentage. Percentage predicted 6MWD was calculated using the equation proposed by Enright et al.\textsuperscript{24}

\[
\text{FOR MEN} \\
\text{6MWD} = \frac{[7.57 \times \text{height (cm)}] - (5.02 \times \text{age}) - [1.76 \times \text{weight (kg)}] - 309 \text{ m}}
\]

\[
\text{FOR WOMEN} \\
\text{6MWD} = \frac{[2.11 \times \text{height (cm)}] - [2.29 \times \text{weight (kg)}] - (5.78 \times \text{age}) + 667 \text{ m}}
\]

The SGRQ is a standardized, self-administered questionnaire for measuring HRQoL in airway disease.\textsuperscript{25} SGRQ consists of three domains (symptoms, impact, and activity) and a total score. Both English and Hindi version of SGRQ were used as per the language preference of the patient. The SGRQ manual was followed for the administration purposes. Total score was computed by weighted sums of the respective items.\textsuperscript{26} The score in SGRQ ranges from 0 (no impairment) to 100 (maximum impairment). A minimally clinically important difference (MCID) of 4 was established for SGRQ by previous research.\textsuperscript{27}

The BI is a multidimensional index, which includes four factors that predict mortality: body mass index, the degree of airflow obstruction, functional dyspnea, and exercise capacity as assessed by the 6MWT.\textsuperscript{28} A higher score indicates greater risk. The BI ranges from 0 to 10 points, with higher scores indicating a greater risk of death. One unit change in the BI has been suggested as clinically significant.\textsuperscript{29}

The patients in PR group attended a structured, comprehensive PR program for six weeks. This PR program was institution based; therefore, the entire exercise protocol was performed under the supervision of a qualified physiotherapist at the hospital. The patients were instructed to report five-times per week at the pulmonary outpatient department. The PR program comprised of stretching of upper and lower extremity muscles, breathing exercises, supervised endurance and resistance training, self-management, and patient education. Patients were administered short-acting bronchodilators (SABDs) through nebulization in both the PR and control groups.

Breathing exercises lasted for 30 minutes in each session and were performed three-to-five times per week for six weeks. Diaphragmatic and pursed-lip breathing were performed as described by previous studies.\textsuperscript{30,31} These exercises have been found to reduce respiratory rate and improve tidal volume as well.

Symptom limited cardiopulmonary exercise testing (CPET) was performed as per the guidelines\textsuperscript{32} on an electronically braked cycle ergometer (ERGOSELECT 200P/200K; Germany) to calculate the exercise intensity from peak oxygen uptake (VO\textsubscript{2peak}) achieved during exercise. VO\textsubscript{2peak} was calculated using a breath-by-breath gas analyzer (COSMED QUARK PFT ergo), which gave data on gases consumed by the patient every 10 seconds. At the beginning of every test, the equipment was calibrated. Incremental exercise protocol was initiated after a period of three minutes rest followed by a three-minute warm-up phase at 0-Watt and was progressed gradually by increasing 5 or 10 Watts according to work rate selection every 60 seconds throughout the exercise phase till the patient got exhausted. The exercise test was followed by three minutes of recovery phase. During the test, patients were encouraged to perform their best and were also instructed to maintain a pedaling frequency of 60 revolutions per minutes (rpm), which was displayed on the digital display of ergometer. VO\textsubscript{2peak} achieved during the exercise test served as the measure of exercise intensity. Each patient in the intervention group then received an individualized endurance training program at an intensity of 70% to 90% of their respective VO\textsubscript{2peak} on a motorized treadmill for 20–60 minutes per session, five-times per week for six weeks. A gradual progression of exercise intensity was made from 60–80% of VO\textsubscript{2peak} over six weeks. During the first two weeks of the program, the intensity was set at 60% of their respective VO\textsubscript{2peak}. Thereafter, it was increased to at least 70% for the next two weeks and finally, up to 80% during the last two weeks of the training program.\textsuperscript{33}

Resistance training of both upper and lower extremity muscles was performed three-times per week at an intensity of 50–70% of one repetition.
maximum (1-RM). Prior to performing the 1-RM testing, two familiarization sessions were conducted without any load. 1-RM strength was measured to determine the greatest amount of weight that the individual could move in a single repetition. A warm-up of three-to-five minutes followed by 10 repetitions with a light load was performed prior to the test to reduce the effect of learning. The 1-RM test was initiated near the suspected maximum to minimize repetition fatigue. All subjects attained the 1-RM within three-to-five attempts. Subjects were allowed to rest for two to three minutes between attempts.\textsuperscript{34} After obtaining the 1-RM, the load at 50–70% of 1-RM was calculated for each exercise. In the lower extremity, quadriceps, hamstring, hip flexors, hip abductors, and hip extensors were exercised. Upper extremity strength training included biceps, triceps, and deltoid muscles. Three sets of 8–10 repetitions of each exercise were performed with two to three minutes rest between sets. Following the rule of gradual progression, exercise intensity was kept at 50% of 1-RM for the first two weeks, 60% of 1-RM for the middle two weeks, and 70% of 1-RM for the last two weeks.\textsuperscript{35}

A structured program educating the patients regarding self-management of the symptoms was given in the intervention group (PR group), which comprised of relaxation techniques to control dyspnea, smoking cessation, and nutritional guidelines as per the individualized recommendation of the nutritionist and avoidance of triggers. The control group continued their activities of daily living along with the medical care in accordance with the standard guidelines by a qualified practitioner.

Data are presented as mean±standard deviation or median (interquartile range). The normality of continuous data was examined using the Shapiro-Wilk test and variables that demonstrated non-normal distribution were log-transformed. Independent \textit{t}-test was used to compare the outcome variables between the PR and the control group at baseline and after six weeks. Standardized mean difference (95% confidence interval) was calculated for the difference observed after six weeks in both

| Variables | PR group (n = 14) | Control group (n = 14) | p-value |
|-----------|------------------|----------------------|---------|
| Age, years | 66.0 ± 8.4       | 67.0 ± 6.29          | 0.762   |
| Height, cm | 164.0 ± 8.8      | 159.0 ± 10.3         | 0.200   |
| Weight, kg | 68.0 ± 12.7      | 58.0 ± 12            | 0.091   |
| BMI, kg/m\(^2\) | 24.0 ± 4.3   | 23.0 ± 5.1           | 0.371   |
| Smoking, pack/year | 11.0 ± 3.25 | 11.0 ± 2.9           | 0.763   |
| FeNO, ppb, median (IQR) | 27.0 (22.5) | 26.0 (21.5)          | 0.466   |
| 6 MWD, m | 305.4 ± 74.0     | 313.0 ± 48.1         | 0.769   |
| 6 MWD, % | 64.2 ± 13.6      | 69.4 ± 12.7          | 0.305   |
| SGRQ | | | |
| Symptoms, % | 63.1 ± 17.8 | 65.4 ± 20.6          | 0.752   |
| Impact, % | 59.9 ± 17.2     | 68.1 ± 19.5          | 0.253   |
| Activity, % | 60.0 ± 16.5 | 65.0 ± 18.3          | 0.429   |
| Total, % | 62.3 ± 17.9      | 65.9 ± 19.5          | 0.612   |
| PFT | | | |
| FEV\(_1\), L | 1.4 ± 0.4   | 1.2 ± 0.2            | 0.236   |
| FEV\(_1\)% predicted | 65.1 ± 26.7 | 62.8 ± 15.6          | 0.671   |
| FVC, L | 2.2 ± 0.2       | 2.0 ± 0.3            | 0.105   |
| FVC % predicted | 71.9 ± 20.9 | 69.2 ± 14.7          | 0.720   |
| FEV\(_1\)/FVC | 47.3 ± 17.9 | 45.5 ± 17.5          | 0.784   |
| Bode index | 9.3 ± 1.3     | 8.2 ± 1.9            | 0.133   |

Values are expressed as mean±standard deviation unless otherwise stated. Significance level: \(p < 0.050\).

PR: pulmonary rehabilitation; BMI: body mass index; FeNO: fractional exhaled nitric oxide; IQR: interquartile range; Eo: eosinophil; 6MWD: six minute walk distance; SGRQ: St. George’s Respiratory Questionnaire; PFT: pulmonary function test; FEV\(_1\): forced expiratory volume in 1 second; FVC: forced vital capacity.
RESULTS

All 28 participants enrolled in the investigation completed the study. The participant’s baseline characteristics are presented in Table 1. There were no significant differences between the PR and the control group for demographic, clinical, and outcome variables at baseline.

After six weeks, there was a significant improvement in 6MWD in the PR group by 96 m when compared to the control group. The magnitude of overall increase in distance walked in the PR group exceeded the MCID of 54 m, which is in agreement with the findings of previous investigations as they also reported an increase of 66 m and 60 m in COPD and asthma patients, respectively, post-PR. In our study, ACOS patients showed a percentage increase of 29.5% in 6MWD after six weeks of PR. This percentage change observed for the 6MWD in our study is greater in comparison to the change observed by previous studies, which were 23% and 25%, respectively. The larger improvement observed in ACOS patients compared to patients with asthma and COPD alone following PR may be due to worse disease status found in ACOS characterized by more dyspnea, a decline in lung function (FEV₁), and lower 6MWD compared to asthma and COPD alone.

DISCUSSION

To the best of our knowledge, this is the first randomized control trial to assess the effectiveness of a comprehensive six-week PR program in patients with ACOS. Findings suggest that a six-week PR intervention is an effective treatment adjunct in improving functional capacity, HRQoL, and BI in ACOS patients.

We observed a significant improvement in 6MWD in the PR group by 96 m when compared to the control group. The magnitude of overall increase in distance walked in the PR group exceeded the MCID of 54 m, which is in agreement with the findings of previous investigations as they also reported an increase of 66 m and 60 m in COPD and asthma patients, respectively, post-PR. In our study, ACOS patients showed a percentage increase of 29.5% in 6MWD after six weeks of PR. This percentage change observed for the 6MWD in our study is greater in comparison to the change observed by previous studies, which were 23% and 25%, respectively. The larger improvement observed in ACOS patients compared to patients with asthma and COPD alone following PR may be due to worse disease status found in ACOS characterized by more dyspnea, a decline in lung function (FEV₁), and lower 6MWD compared to asthma and COPD alone.

Table 2: Standardized mean difference of outcome variables after six weeks between the groups.

| Outcome variables | PR group (n = 14) | Control group (n = 14) | PR group vs. control group Standardized mean difference (95% CI), p-value |
|-------------------|------------------|-----------------------|---------------------------------------------------------------------|
| 6MWD, m           | Baseline 305.4 ± 74.0, Six weeks 401.9 ± 63.5 | Baseline 313.0 ± 48.1, Six weeks 321.2 ± 43.4 | 1.44 (0.60,2.29), 0.001* |
| 6MWD, % Pred      | Baseline 64.2 ± 13.6, Six weeks 83.2 ± 11.4 | Baseline 69.4 ± 12.7, Six weeks 71.1 ± 12.6 | 0.98 (0.19,1.77), 0.014* |
| SGRQ              |                  |                       |                                                                     |
| Symptoms, %       | Baseline 63.1 ± 17.8, Six weeks 42.3 ± 12.4 | Baseline 65.4 ± 20.6, Six weeks 61.5 ± 19.8 | -1.49 (-2.34,-0.64), 0.005* |
| Impact, %         | Baseline 59.9 ± 17.2, Six weeks 44.4 ± 13.0 | Baseline 68.1 ± 19.5, Six weeks 63.3 ± 16.9 | -1.22 (-2.03,-0.40), 0.003* |
| Activity, %       | Baseline 60.0 ± 16.5, Six weeks 43.7 ± 12.0 | Baseline 65.0 ± 18.3, Six weeks 63.3 ± 18.3 | -1.22 (-2.03,-0.40), 0.003* |
| Total, %          | Baseline 62.3 ± 17.9, Six weeks 45.5 ± 13.1 | Baseline 65.9 ± 19.5, Six weeks 64.3 ± 20.0 | -1.15 (-1.96,-0.34), 0.007* |
| PFT               |                  |                       |                                                                     |
| FEV₁, L           | Baseline 1.4 ± 0.4, Six weeks 1.5 ± 0.5 | Baseline 1.2 ± 0.2, Six weeks 1.2 ± 0.2 | 0.51 (-0.25,1.26), 0.182 |
| %Δ in FEV₁        | Baseline 65.1 ± 26.7, Six weeks 69.3 ± 31 | Baseline 62.8 ± 15.6, Six weeks 64.7 ± 16.4 | 0.18 (-0.56,0.92), 0.630 |
| FVC, L            | Baseline 2.2 ± 0.2, Six weeks 2.3 ± 0.3 | Baseline 2.0 ± 0.3, Six weeks 2.1 ± 0.3 | 0.02 (-0.72,0.76), 0.105 |
| %Δ in FVC         | Baseline 71.9 ± 20.9, Six weeks 74.4 ± 20.2 | Baseline 69.2 ± 14.7, Six weeks 70.4 ± 20.2 | 0.27 (-0.47,1.02), 0.720 |
| FEV₁/FVC          | Baseline 47.3 ± 17.9, Six weeks 49.7 ± 18.1 | Baseline 45.5 ± 17.5, Six weeks 47.0 ± 17.2 | 0.14 (-0.61,0.88), 0.697 |
| Bode index        | Baseline 9.3 ± 1.3, Six weeks 6.3 ± 1.6 | Baseline 8.2 ± 1.9, Six weeks 8.5 ± 1.9 | -1.22 (-2.03,-0.40), < 0.001* |

Values are presented as mean±standard deviation.
*Significant difference between groups following six weeks.
PR: pulmonary rehabilitation, CI: confidence interval, 6MWD: six minute walk distance, SGRQ: St. George’s Respiratory Questionnaire, PFT: pulmonary function test, FEV₁: forced expiratory volume in 1 second, %Δ in FEV₁: percentage change in forced expiratory volume in 1 second; FVC: forced vital capacity, %Δ in FVC: percentage change in forced vital capacity.
Two large systematic reviews and meta-analyses conducted on ACOS have affirmed these findings by demonstrating that patients with ACOS have a greater symptomatic burden.\textsuperscript{38,39} We may speculate that patients with worse disease status tend to have a larger capacity to improve compared to patients with more preserved lung function and exercise capacity, in particular, reference to change in 6MWD.

We found a significant improvement in all domains of SGRQ following PR; symptom domain (\(-20.8\) units), impact domain (\(-15.5\) units), activity domain (\(-16.3\) units), and in the total score (\(-16.8\) units). The magnitude of decline observed in all the domains of SGRQ post-PR exceeded the previously reported MCID (decline of 4 points or more)\textsuperscript{27} The changes observed in all domains are greater than previously conducted investigations\textsuperscript{40,41} Thus, greater responsiveness of the SGRQ at the end of PR in patients with ACOS compared to patients with asthma and COPD alone may arise as physiological measures related to greater severity of breathlessness, airflow limitation and exercise capacity, which are significant contributors to variance for the total scores of the SGRQ. Furthermore, our study demonstrated that the specific domains of the SGRQ also showed good responsiveness providing the clinician with information regarding changes experienced in relation to symptoms, activity, and impact of the disease. Additionally, at the end of the six-week PR program, the symptom domain showed the highest responsiveness, which might be because of the severity of breathlessness, which has been reported to be higher in patients with ACOS.

We found no improvement in pulmonary function measures in patients with ACOS post-PR. In the context of pulmonary function, there exists contradictory literature. A few investigations conducted previously demonstrated an improvement in pulmonary function,\textsuperscript{16,17} while others have reported no changes\textsuperscript{42,43} in these parameters post-PR. Our result is in accordance with the previous studies,\textsuperscript{42,43} which have demonstrated that the training benefits of rehabilitation are independent of changes in pulmonary function measures. Recent studies\textsuperscript{44,45} have also found no significant improvement in PFT following four and eight weeks of PR in COPD patients. The reason for this in our study can be persistent airflow limitation in ACOS group of patients, which might have failed to respond to short-term PR program.\textsuperscript{46}

The BI is considered as an important predictor of mortality.\textsuperscript{29} Chung et al.\textsuperscript{10} reported that ACOS patients have high mortality, which is considered likely due to co-morbidities contributing to health impairment. BI is considered not only an effective prognostic tool for COPD, but its use and validation has also been reported in ACOS.\textsuperscript{6} We observed a significant improvement in BI (\(-3\) unit) in the PR group following six weeks, which exceeded the clinically important difference of 1 unit.\textsuperscript{47} We found that PR has no significant effect on pulmonary measures, but it significantly improved dyspnea and exercise capacity. These two outcomes, dyspnea and exercise capacity, are components of the BI and thus might have contributed to significant positive change in this index as well.\textsuperscript{48,49} In our study, the magnitude of decline in BI was greater than that reported in a previous study,\textsuperscript{50} which reported a decline of 2 units post-PR in COPD patients. The greater decline we saw may be due to changes in two components of the BI (i.e., dyspnea and exercise capacity).

The main limitation of our study is the incorporation of short-term PR and, therefore, future research should combat this gap, and it would be interesting to examine the effect of a long-term PR in the unique population of ACOS. Although statistical power was calculated for the study, the sample seemed to be small and, thus, the effect of PR should be assessed on a larger sample in the future. Inclusion of other more relevant outcome variables such as arterial blood gas analysis and inflammatory markers such as Th2 would give a clear picture regarding physiological adaptations to PR in ACOS.

\textbf{CONCLUSION}

A short-term PR program in ACOS patient’s results in favorable changes in the functional capacity, HRQoL, and BI. However, short-term PR was not sufficient to register changes in pulmonary function in these patients; therefore, it is important that further long-term randomized control trials should be conducted among this patient group. The findings of our study will pave the way for clinicians in optimizing the effectiveness of PR in patients with ACOS and to gauge the responsiveness of these patients following short-term PR.
Disclosure
All authors declared no conflict of interest. No funding was received for this study.

REFERENCES
1. Asthma GIf. Diagnosis of diseases of chronic airflow limitation: Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). 2015 [cited 2019 3 May]. Available from: https://www.mscbs.gob.es/organizacion/sns/planCalidadSNS/pdf/GOLD_ACOS_2015.pdf.
2. Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol 2016 Oct;138(4):977-983.
3. Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med 2016 Jan;110:1-11.
4. GOLD. Diagnosis of diseases of chronic airflow limitation: asthma COPD and asthma-COPD overlap syndrome (ACOS) based on the global strategy for asthma management and prevention and the global strategy for the diagnosis, Management and Prevention of COPD GOLD and GINA. 2014; 1-18 [cited 2019 3 May]. Available from: https://ginasthma.org/wp-content/uploads/2019/11/GINA-GOLD-ACOS_2014.pdf.
5. Tripathi PM, Kant S, Yadav RS, Kushwaha RA, Prakash V, Rizvi SH, et al. Expression of toll-like receptor 2 and 4 in peripheral blood neutrophil cells from patients with chronic obstructive pulmonary disease. Oman Med J 2017 Nov;32(6):477-485.
6. Hardin M, Cho M, McDonald ML, Beatty T, Ramsdell J, Bhatt S, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014 Aug;44(2):341-350.
7. Kostikas K, Clemens A, Patalano F. The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease? Int J Chron Obstruct Pulmon Dis 2016 Jan;11:1297-1306.
8. Ding B, Enstone A. Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): structured literature review and physician insights. Expert Rev Respir Med 2016;10(3):363-371.
9. Pleasant RJ, O'hara JA, Croft JB, Liu Y, Kraft M, Mannino DM, et al. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD 2014 Jun;11(3):256-266.
10. Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH. Characteristics and self-rated health of overlap syndrome. Int J Chron Obstruct Pulmon Dis 2014 Jul;9:795-804.
11. Spruit MA, Singh SJ, Garvey C, ZuWällack R, Nici L, Rochester C, et al. ATS/ERS Task Force on Pulmonary Rehabilitation: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013 Oct;188(8):e13-e64.
12. Cheriamance D, Joshi V, Agarwal K, Purohit G, Choudhary C, Parle S. The effect of 6 week pulmonary rehabilitation in COPD—a randomized control study. Chest 2013;144(4):785A.
13. Lingner H, Ernst S, Großhennig A, Djağangiri N, Scheub D, Wittmann M, et al. Asthma control and health-related quality of life one year after inpatient pulmonary rehabilitation: the ProKAR Study. J Asthma 2015;52(6):614-621.
14. Troosters T, Vilaro J, Rabinovich R, Casas A, Barberà JA, Rodriguez-Roisin R, et al. Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 Sep;20(3):564-569.
15. Rejhi IB, Trabelsi Y, Chouchene A, Ben Turki W, Ben Saad H, Zhidi A, et al. Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects. Int J Chron Obstruct Pulmon Dis 2010 Aug;5:209-215.
16. Elkhateeb NB, Elhaddi AI, Masood HH, Mohammed AR. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 2015;64:359-369.
17. Topalovic M, Helsen T, Troosters T, Janssens W. Unexpected improvements of lung function in chronic obstructive pulmonary disease. Respir Med Case Rep 2016 May;18:221-225.
18. Araújo D, Padrão E, Morais-Almeida M, Cardoso J, Pavão F, Leite RB, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a Portuguese consensus. Rev Port Pneumol (2006) 2017 Mar-Apr;23(2):90-99.
19. Karapolat H, Atasever A, Atanaz F, Kirazli Y, Elmans F, Erdinç E. Do the benefits gained using a short-term pulmonary rehabilitation program remain in COPD patients after participation? Lung 2007 Jul-Aug;185(4):221-225.
20. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun;23(6):932-946.
21. Laszlo G. Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax 2006 Sep;61(9):744-746.
22. Zakaria R, Harif N, Al-Rabhi B, Aziz CB, Ahmad AH. Gender differences and obesity influence on pulmonary function parameters. Oman Med J 2019 Jan;34(1):44-48.
23. Holland AE, Spruit MA, Troosters T, Puhin MA, Pepin V, Sacy D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014 Dec;44(6):1428-1446.
24. Enright PL, Sherrell DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998 Nov;158(5 Pt 1):1384-1387.
25. Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Reser 2000 Sep;22(9):1121-1145.
26. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med 1991 Sep;84(Suppl B):25-31, discussion 33-37.
27. Alma H, de Jong C, Jelsusic D, Wittmann M, Schuler M, Floksstra-de Blok B, et al. Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference. NPJ Prim Care Respir Med 2016 Sep;26:16041.
28. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar;350(10):1005-1012.
29. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005 Oct;26(4):630-636.
30. Gosselink R. Controlled breathing and dyspnea in patients with chronic obstructive pulmonary disease (COPD). J Rehabil Res Dev 2003 Sep-Oct;40(5(Suppl 2)):25-33.
31. Dechman G, Wilson CR. Evidence underlying breathing retraining in people with stable chronic obstructive pulmonary disease. Phys Ther 2004 Dec;84(12):1189-1197.
32. American Thoracic Society: American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003 Jan;167(2):211-277.
33. Sala E, Roca J, Marrades RM, Alonso J, Gonzalez De Saso JM, Moreno A, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Jun;159(6):1726-1734.
34. Daabis R, Hassan M, Zidan M. Endurance and strength training in pulmonary rehabilitation for COPD patients. Egypt J Chest Dis Tuberc 2017;66(2):231-236.
35. Bernard S, Whitfam F, Leblanc P, Jobin J, Belleau R, Bérubé C, et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Mar;159(3):896-901.

36. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997 Apr;155(4):1278-1282.

37. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. A new approach to grading and treating COPD based on clinical phenotypes; summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013 Mar;22(1):117-121.

38. Alshabanat A, Zafari Z, Albayamy O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS One 2015 Sep;10(9):e0136065.

39. Nielsen M, Bårnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome—a systematic review. Int J Chron Obstruct Pulmon Dis 2015 Jul;10:1443-1454.

40. Kon SS, Dilaver D, Mittal M, Nolan CM, Clark AL, Canavan JL, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax 2014 Sep;69(9):793-798.

41. Vagaggini B, Costa F, Antonelli S, De Simone C, De Cusatis G, Martino F, et al. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. Respir Med 2009 Aug;103(8):1224-1230.

42. Niederman MS, Clemente PH, Fein AM, Feinsilver SH, Robinson DA, Illowite JS, et al. Benefits of a multidisciplinary pulmonary rehabilitation program. Improvements are independent of lung function. Chest 1991 Apr;99(4):798-804.

43. Vogiatzis I, Williamson AF, Miles J, Taylor IK. Physiological response to moderate exercise workloads in a pulmonary rehabilitation program in patients with varying degrees of airflow obstruction. Chest 1999 Nov;116(5):1200-1207.

44. Sahin H, Naz I, Varol Y, Aksel N, Tüksavul F, Ozsoz A. COPD patients with severe diffusion defect in carbon monoxide diffusing capacity predict a better outcome for pulmonary rehabilitation. Rev Port Pneumol (2006) 2016 Nov-Dec;22(6):323-330.

45. Ferreira G, Feuerman M, Spiegler P. Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2006 Jan-Feb;26(1):54-60.

46. Akwe J, Miller A. Asthma chronic obstructive pulmonary disease overlap syndrome (ACOS): where we stand. International Journal of Clinical and Experimental Medical Sciences 2016;2(4):59-66.

47. Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016 Dec;12:CD005305.

48. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995 Jun;122(11):823-832.

49. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000 Aug;109(3):207-212.

50. Barakat S, Michele G, George P, Nicole V, Guy A. Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3(1):155-162.